American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2010
Rare genotype combination of the serotonin transporter gene associated with treatment response in severe personality disorder.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Perroud Nader, Salzmann Annick, Saiz Pilar A, Baca-Garcia Enrique, Sarchiapone Marco, Garcia-Portilla Maria P, Carli Vladimir, Vaquero-Lorenzo Concepción, Jaussent Isabelle, Mouthon Dominique, Vessaz Monique, Huguelet Philippe, Courtet Philippe, Malafosse Alain, European Research Consortium for Suicide (EURECA)
Аннотация
The insertion deletion (ins/del) polymorphism of the serotonin transporter gene (5-HTTLPR) has been associated with several psychiatric phenotypes and antidepressant's response. We investigated, in a large cohort of 5,608 controls and subjects suffering from various psychiatric disorders, the frequency of haplotypes and corresponding genotypes combining the 5-HTTLPR and the other serotonin transporter promoter functional variant (rs25531). We showed that rs25531 lies 18 bp 5' to the site where the 43 bp (and not 44 bp as previously described) ins/del defines the 14- and 16-repeat alleles. These polymorphisms should therefore be considered as four alleles instead of a triallelic unique locus. The very rare G-14/G-16 genotype was carried on by only three subjects. These are women with a history of suicide attempt with a psychiatric history strongly suggesting a borderline personality disorder. Two of them have shown a non-response to serotoninergic antidepressant. Interestingly, in one of them was observed a spectacular response after the introduction of bupropion. The genotyping droved our therapeutic approach, by preferring a dopaminergic over a serotoninergic agent. This study highlights the usefulness of studying very rare clinical cases as well as rare variants, in order to deal with the biological heterogeneity of spectral disorders. © 2010 Wiley-Liss, Inc.
Предметные рубрики MeSH
AdultAllelesAntidepressive AgentsBorderline Personality DisorderCase-Control StudiesFemaleGene FrequencyGenotypeHaplotypesHumansINDEL MutationMaleMental DisordersMiddle AgedPolymerase Chain ReactionPolymorphism, GeneticPromoter Regions, GeneticSerotonin Plasma Membrane Transport ProteinsSelective Serotonin Reuptake InhibitorsTreatment Outcome